Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
06 September 2023 - 9:00PM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced the publication of a study evaluating tegoprubart as an
immunomodulatory monotherapy in nonhuman primate kidney and islet
allotransplants. The study, entitled “The anti-CD40L monoclonal
antibody AT-1501 promotes islet and kidney allograft survival and
function in nonhuman primates”, was published in the August 30,
2023, issue of Science Translational Medicine.
Results from the study showed that treatment with tegoprubart as
a monotherapy promoted long-term kidney and islet allograft
survival and function in nonhuman primates, indicating its
potential as an immunomodulatory agent for organ transplantation.
In the study, tegoprubart did not bind to Fc receptors or promote
platelet aggregation in vivo, thereby minimizing the risk of
thromboembolic complications, while also retaining a high binding
affinity to CD40L. Additionally, phenotypes of both CD4+ and CD8+
cells remained similar throughout the study.
“These findings published in Science Translational Medicine
further support our hypothesis that Eledon’s anti-CD40L antibody,
tegoprubart, has the potential to play a crucial role in modulating
the immune system to help protect transplanted organs and thereby
promote graft function and survival in kidney transplant patients,”
said Dr. Steve Perrin, Eledon’s President and Chief Scientific
Officer. “We look forward to presenting additional tegoprubart
human data in kidney transplantation at Kidney Week in
November.”
Eledon recently initiated the BESTOW study, a phase 2 study
enrolling approximately 120 participants undergoing kidney
transplantation to assess the efficacy and safety of tegoprubart
compared to the standard of care (tacrolimus). The Company
previously reported clinical data at the World Congress of
Nephrology from its ongoing Phase 1b study evaluating tegoprubart
in kidney transplantation, demonstrating no incidence of acute
rejection and strong graft function in the first three enrolled
participants. Eledon expects to report updated clinical data from
the Phase 1b study at the American Society of Nephrology (ASN)
Kidney Week Annual Meeting in November 2023.
About Eledon Pharmaceuticals and tegoprubart
(formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology
company using its immunology expertise to develop therapies that
protect transplanted organs and prevent organ rejection, as well as
to treat amyotrophic lateral sclerosis (ALS). The Company’s lead
compound in development is tegoprubart, an anti-CD40L antibody with
high affinity for CD40 Ligand, a well-validated biological target
with broad therapeutic potential. Eledon is headquartered
in Irvine, California. For more information, please visit the
company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social
media: LinkedIn; Twitter
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Any statements about
planned clinical trials and the Company’s other future
expectations, plans and prospects, as well as other statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
“estimates,” “intends,” “predicts,” “projects,” “targets,” “looks
forward,” “could,” “may,” and similar expressions, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are inherently uncertain and are subject to numerous
risks and uncertainties, including: risks relating to the safety
and efficacy of our drug candidates; risks relating to clinical
development timelines, including interactions with regulators and
clinical sides, as well as patient enrollment; risks relating to
costs of clinical trials and the sufficiency of the company’s
capital resources to fund planned clinical trials; and risks
associated with the impact of the ongoing coronavirus pandemic.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various factors. These
risks and uncertainties, as well as other risks and uncertainties
that could cause the company’s actual results to differ
significantly from the forward-looking statements contained herein,
are discussed in our quarterly 10-Q, annual 10-K, and other filings
with the U.S. Securities and Exchange Commission, which can be
found at www.sec.gov. Any forward-looking statements contained
in this press release speak only as of the date hereof and not of
any future date, and the company expressly disclaims any intent to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Apr 2024 to May 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From May 2023 to May 2024